Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis

Discovery of novel reversible inhibitor of DprE1 based on benzomorpholine for the treatment of tuberculosis

ABSTRACT About a quarter of the world’s population is infected with Mycobacterium tuberculosis, equivalent to about two billion people. With the emergence of multidrug-resistant tuberculosis, those existing anti-tuberculosis drugs no longer meet the demand for cure anymore; there is an urgent need f...

Full description

Bibliographic Details
Main Authors: Wang Xiang, Hualong He, Xianjie Duan, Zhiqun He, Xinyue Xu, Mengya Liao, Fei Teng, Xiao Li, Tianwen Luo, Jumei Zeng, Luoting Yu, Chao Gao
Format: Article
Language:English
Published: American Society for Microbiology 2023-10-01
Series:Microbiology Spectrum
Subjects:
tuberculosis
DprE1
benzomorpholine
antimycobacterial agents
Online Access:https://journals.asm.org/doi/10.1128/spectrum.04721-22

Internet

https://journals.asm.org/doi/10.1128/spectrum.04721-22

Similar Items